Recent corporate updates for Compass Therapeutics (CMPX) center on preparations for a potential Biologics License Application (BLA) submission for its lead oncology asset, tovecimig, following positive clinical trial outcomes. Meanwhile, institutional analysts have adjusted their intermediate price targets following quarterly balance sheet disclosures.